Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 291
Filtrar
1.
Arq. ciências saúde UNIPAR ; 26(3)set-dez. 2022.
Artículo en Portugués | LILACS | ID: biblio-1399128

RESUMEN

A pandemia de COVID-19 e as medidas de controle para conter a disseminação do vírus, como o distanciamento social, trouxeram mudanças à rotina das pessoas, mundialmente. Esse contexto pode gerar impactos adversos para a saúde mental dos indivíduos, especialmente, àqueles em maior vulnerabilidade, os idosos. O objetivo desse estudo foi analisar na literatura os impactos reais e/ou potenciais da pandemia de COVID-19 na saúde mental de idosos. Trata-se de uma revisão integrativa de literatura com buscas realizadas na Biblioteca Virtual em Saúde, que utilizou a seguinte estratégia de busca: (Coronavírus OR "Infecções por Coronavirus" OR "Coronavirus Infections" OR COVID-19) AND (idoso OR elderly OR aged) AND ("Saúde Mental" OR "Mental Health"). Foram critérios de inclusão: artigos acessados na íntegra, sem distinção de ano e idioma, indexados até o dia 11 de novembro de 2020; e os critérios de exclusão: artigos com fuga do escopo da pesquisa, revisões de literatura, arquivos multimídia e duplicados. Foram encontrados 241 registros, e após a aplicação dos critérios de elegibilidade estabelecidos restaram 27 artigos para discussão. Dentre os impactos reais/potenciais da pandemia de COVID-19 na saúde mental dos idosos, abordados nos estudos, destaca-se a ansiedade, depressão, solidão, estresse, sensação de medo ou pânico, tristeza, suicídio/ideação suicida e insônia. Apesar disso, considera-se que há uma quantidade ainda escassa de estudos voltados especificamente para a população idosa que permitam aprofundar as discussões sobre esse tema.


The COVID-19 pandemic and control measures to contain the spread of the virus, such as social detachment, have brought changes to people's routine, worldwide. This context can generate adverse impacts on the mental health of individuals, especially those most vulnerable, the older adults. The aim of this study was to analyze in the literature the real and / or potential impacts of the COVID-19 pandemic on the mental health of the older adults. It is an integrative literature review with searches performed in the Virtual Health Library, which used the following search strategy: (Coronavírus OR "Infecções por Coronavirus" OR "Coronavirus Infections" OR COVID- 19) AND (idoso OR elderly OR aged) AND ("Saúde Mental" OR "Mental Health"). Inclusion criteria were: articles accessed in full, without distinction of year and language, indexed until November 11, 2020; and exclusion criteria: articles with escape the scope of the research, literature reviews, multimedia and duplicate files, 241 records were found, and after applying the established eligibility criteria, 27 articles remained for discussion, among the actual / potential impacts of the COVID-19 pandemic on older people, addressed in the studies, anxiety, depression, loneliness, stress, feeling of fear or panic, sadness, suicide / suicidal ideation and insomnia stand out. Despite this, there is still a small amount studies specifically aimed at the older population that allow further discussions on this topic.


La pandemia de covid-19 y las medidas de control para contener la propagación del virus, como el distanciamiento social, han supuesto cambios en la rutina de las personas en todo el mundo. Este contexto puede generar impactos adversos a la salud mental de los individuos, especialmente a los más vulnerables, los ancianos. El objetivo de este estudio fue analizar en la literatura los impactos reales y/o potenciales de la pandemia de COVID-19 en la salud mental de los ancianos. Se trata de una revisión bibliográfica integradora con búsquedas realizadas en la Biblioteca Virtual de Salud, que utilizó la siguiente estrategia de búsqueda: (Coronavirus OR "Coronavirus Infections" OR "Coronavirus Infections" OR COVID-19) AND (elderly OR aged) AND ("Mental Health" OR "Mental Health"). Los criterios de inclusión fueron: artículos accedidos en su totalidad, independientemente del año y el idioma, indexados hasta el 11 de noviembre de 2020; y los criterios de exclusión: artículos que estuvieran fuera del ámbito de la investigación, revisiones bibliográficas, archivos multimedia y duplicados. Se encontraron un total de 241 registros, y tras aplicar los criterios de elegibilidad establecidos, quedaron 27 artículos para su discusión. Entre los impactos reales/potenciales de la pandemia de COVID-19 en la salud mental de los ancianos, abordados en los estudios, destacan la ansiedad, la depresión, la soledad, el estrés, la sensación de miedo o pánico, la tristeza, la ideación suicida/suicida y el insomnio. A pesar de ello, se considera que todavía hay una escasa cantidad de estudios dirigidos específicamente a la población de edad avanzada que permitan profundizar en las discusiones sobre este tema.


Asunto(s)
Anciano/psicología , Salud Mental , Infecciones por Coronavirus/etiología , Pandemias/estadística & datos numéricos , Ansiedad/psicología , Pánico , Suicidio/psicología , Envejecimiento/fisiología , Depresión/psicología , Miedo/psicología , Tristeza/psicología , Distrés Psicológico , Trastornos del Inicio y del Mantenimiento del Sueño/etiología , Soledad/psicología
2.
ScientificWorldJournal ; 2021: 4553890, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34812249

RESUMEN

Avian infectious bronchitis virus is a highly contagious disease occurring in respiratory, urogenital, and reproductive tissues of chicken causing considerable losses due to death, egg drop, and reduced production. This preliminary study was conducted to investigate the prevalence of antibodies against infectious bronchitis virus (IBV) and to assess the potential risk factors in chickens of northwest Ethiopia. A cross-sectional study was conducted from November 2020 to June 2021. A total of 768 serum samples from three zones were collected. To investigate the presence of antibodies against IBV, the indirect ELISA serological test was applied. Positivity for anti-IBV antibodies was observed in 23.96% (95% CI: 20.98-27.14) of the samples. The mixed-effect logistic regression analysis of potential risk factors showed that IBV prevalence was significantly higher in young chickens than adults (p < 0.001) and higher in intensive farm type than in extensive type (p < 0.001). Based on the production purposes of the chickens, the odds of seropositivity for IB was significantly higher in layers than in broilers (p < 0.001) and dual purposes (p < 0.001). This study revealed higher seroprevalence in farms which had the "all-in-all-out" rearing method than in farms with different batches in one house with a significant difference (p < 0.001), higher seroprevalence in the poor ventilated type than in good ones (p < 0.001), and higher seroprevalence in the houses that did not remove used litter at all than houses of completely disposed and partially disposed litter (p=0.002). Moreover, disinfection of houses had significant effect on the occurrence of IB. Having personal protective equipment was significantly affecting the occurrence of IB, being higher in the farms that have no wearing clothes and shoe than in those having wearing clothes and shoe (p=0.002). In conclusion, the seroprevalence finding in the present study indicated that the organism is circulating among the population of chickens and high enough to cause significant economic losses Therefore, poultry houses should be cleaned, disinfected, and well ventilated and farm attendants should have separate farm shoe and clothes. Further studies on the virus isolation and molecular characterization of the target gene are needed in the study area.


Asunto(s)
Infecciones por Coronavirus/veterinaria , Virus de la Bronquitis Infecciosa , Enfermedades de las Aves de Corral/epidemiología , Animales , Pollos/virología , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/etiología , Estudios Transversales , Ensayo de Inmunoadsorción Enzimática , Etiopía/epidemiología , Femenino , Vivienda para Animales , Masculino , Enfermedades de las Aves de Corral/etiología , Enfermedades de las Aves de Corral/virología , Factores de Riesgo , Estudios Seroepidemiológicos
3.
Recurso de Internet en Inglés, Español, Francés, Portugués | LIS | ID: lis-48231

RESUMEN

A diretora da Organização Pan-Americana da Saúde (OPAS), Carissa F. Etienne, advertiu que a interrupção contínua dos serviços de saúde da mulher devido à COVID-19 poderia “destruir” mais de 20 anos de progresso na redução da mortalidade materna e o aumento do acesso ao planejamento familiar na América Latina e no Caribe.


Asunto(s)
Infecciones por Coronavirus/etiología , Betacoronavirus , Salud Materna , Mujeres Embarazadas , Américas/epidemiología , Mortalidad Materna/tendencias
4.
Sci Adv ; 7(25)2021 06.
Artículo en Inglés | MEDLINE | ID: mdl-34134991

RESUMEN

Infection by highly pathogenic coronaviruses results in substantial apoptosis. However, the physiological relevance of apoptosis in the pathogenesis of coronavirus infections is unknown. Here, with a combination of in vitro, ex vivo, and in vivo models, we demonstrated that protein kinase R-like endoplasmic reticulum kinase (PERK) signaling mediated the proapoptotic signals in Middle East respiratory syndrome coronavirus (MERS-CoV) infection, which converged in the intrinsic apoptosis pathway. Inhibiting PERK signaling or intrinsic apoptosis both alleviated MERS pathogenesis in vivo. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV induced apoptosis through distinct mechanisms but inhibition of intrinsic apoptosis similarly limited SARS-CoV-2- and SARS-CoV-induced apoptosis in vitro and markedly ameliorated the lung damage of SARS-CoV-2-inoculated human angiotensin-converting enzyme 2 (hACE2) mice. Collectively, our study provides the first evidence that virus-induced apoptosis is an important disease determinant of highly pathogenic coronaviruses and demonstrates that this process can be targeted to attenuate disease severity.


Asunto(s)
Antivirales/farmacología , Apoptosis/efectos de los fármacos , Tratamiento Farmacológico de COVID-19 , Infecciones por Coronavirus/tratamiento farmacológico , eIF-2 Quinasa/metabolismo , Adenina/análogos & derivados , Adenina/farmacología , Enzima Convertidora de Angiotensina 2/genética , Animales , Apoptosis/fisiología , COVID-19/etiología , COVID-19/patología , Línea Celular , Infecciones por Coronavirus/etiología , Infecciones por Coronavirus/patología , Dipeptidil Peptidasa 4/genética , Células Epiteliales/virología , Femenino , Humanos , Indoles/farmacología , Pulmón/virología , Masculino , Ratones Transgénicos , eIF-2 Quinasa/antagonistas & inhibidores , eIF-2 Quinasa/genética
5.
Infect Genet Evol ; 93: 104944, 2021 09.
Artículo en Inglés | MEDLINE | ID: mdl-34052418

RESUMEN

Since the emergence of their primitive strains, the complexity surrounding their pathogenesis, constant genetic mutation and translation are contributing factors to the scarcity of a successful vaccine for coronaviruses till moment. Although, the recent announcement of vaccine breakthrough for COVID-19 renews the hope, however, there remains a major challenge of accessibility to urgently match the rapid global therapeutic demand for curtailing the pandemic, thereby creating an impetus for further search. The reassessment of results from a stream of experiments is of enormous importance in identifying bona fide lead-like candidates to fulfil this quest. This review comprehensively highlights the common pathomechanisms and pharmacological targets of HCoV-OC43, SARS-CoV-1, MERS-CoV and SARS-CoV-2, and potent therapeutic potentials from basic and clinical experimental investigations. The implicated targets for the prevention and treatment include the viral proteases (Mpro, PLpro, 3CLpro), viral structural proteins (S- and N-proteins), non-structural proteins (nsp 3, 8, 10, 14, 16), accessory protein (ns12.9), viroporins (3a, E, 8a), enzymes (RdRp, TMPRSS2, ADP-ribosyltransferase, MTase, 2'-O-MTase, TATase, furin, cathepsin, deamidated human triosephosphate isomerase), kinases (MAPK, ERK, PI3K, mTOR, AKT, Abl2), interleukin-6 receptor (IL-6R) and the human host receptor, ACE2. Notably among the 109 overviewed inhibitors include quercetin, eriodictyol, baicalin, luteolin, melatonin, resveratrol and berberine from natural products, GC373, NP164 and HR2P-M2 from peptides, 5F9, m336 and MERS-GD27 from specific human antibodies, imatinib, remdesivir, ivermectin, chloroquine, hydroxychloroquine, nafamostat, interferon-ß and HCQ from repurposing libraries, some iron chelators and traditional medicines. This review represents a model for further translational studies for effective anti-CoV therapeutic designs.


Asunto(s)
Antivirales/farmacología , Infecciones por Coronavirus/etiología , Coronavirus/patogenicidad , Interacciones Huésped-Patógeno , Antivirales/uso terapéutico , Coronavirus/efectos de los fármacos , Coronavirus/metabolismo , Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/virología , Coronavirus Humano OC43/efectos de los fármacos , Coronavirus Humano OC43/patogenicidad , Humanos , Coronavirus del Síndrome Respiratorio de Oriente Medio/efectos de los fármacos , Coronavirus del Síndrome Respiratorio de Oriente Medio/patogenicidad , Ensayos Clínicos Controlados Aleatorios como Asunto , SARS-CoV-2/efectos de los fármacos , SARS-CoV-2/patogenicidad , Proteínas Virales/química , Proteínas Virales/genética , Proteínas Virales/metabolismo
6.
Libyan J Med ; 16(1): 1910195, 2021 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-33797350

RESUMEN

The outbreak of corona virus disease (COVID-19) caused by the new severe acute respiratory syndrome corona virus 2 began in Wuhan, China, resulting in respiratory disorders. In January of 2020, the World Health Organization declared the outbreak a pandemic owing to its global spread. Because no studies have investigated COVID-19 in Saudi Arabia, this study investigated similarities and differences between demographic data during the COVID-19 and Middle East respiratory syndrome (MERS) outbreaks in Saudi Arabia. A retrospective trend analysis was performed to assess demographic data of all laboratory-confirmed MERS and COVID-19 cases. Patients' charts were reviewed for data on demographics, mortality, citizenship, sex ratio, and age groups with descriptive and comparative statistics; the data were analyzed using a non-parametric binomial test and chi-square test. Of all COVID-19 patients in Saudi Arabia,78%were male patients and 22% were female patients. This proportion of male COVID-19 patients was similar to that of male MERS patients, which also affected male patients more frequently than female patients. The number of COVID-19-positive Saudi cases was lower than that of non-Saudi cases, which were in contrast to that of MERS; COVID-19 appeared to be remarkably similar to MERS with respect to recovered cases. However, the numbers of critical and dead COVID-19 patients have been much lower than those of MERS patients. The largest proportion of COVID-19 and MERS cases (44.05% and 40.8%, respectively) were recorded in the Western region. MERS and COVID-19 exhibited similar threats to the lives of adults and the elderly, despite lower mortality rates during the COVID-19 epidemic. Targeted prevention of and interventions against MERS should be allocated populations according to the areas where they inhabit. However, much more information regarding the dynamics and epidemiology of COVID-19 in Saudi Arabia is needed.Abbrevation : MERS: Middle East Respiratory syndrome; COVID-19: Corona Virus Disease 2019.


Asunto(s)
COVID-19/epidemiología , Infecciones por Coronavirus/epidemiología , Brotes de Enfermedades , SARS-CoV-2 , Adolescente , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , COVID-19/etiología , Niño , Preescolar , Infecciones por Coronavirus/etiología , Demografía , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Arabia Saudita/epidemiología , Factores Sexuales , Adulto Joven
7.
Blood Adv ; 5(7): 1903-1914, 2021 04 13.
Artículo en Inglés | MEDLINE | ID: mdl-33792629

RESUMEN

Data are limited regarding risk factors for lower respiratory tract infection (LRTI) caused by seasonal human coronaviruses (HCoVs) and the significance of virologic documentation by bronchoalveolar lavage (BAL) on outcomes in hematopoietic cell transplant (HCT) recipients. We retrospectively analyzed patients undergoing allogeneic HCT (4/2008-9/2018) with HCoV (OC43/NL63/HKU1/229E) detected by polymerase chain reaction during conditioning or post-HCT. Risk factors for all manifestations of LRTI and progression to LRTI among those presenting with HCoV upper respiratory tract infection (URTI) were analyzed by logistic regression and Cox proportional hazard models, respectively. Mortality rates following HCoV LRTI were compared according to virologic documentation by BAL. A total of 297 patients (61 children and 236 adults) developed HCoV infection as follows: 254 had URTI alone, 18 presented with LRTI, and 25 progressed from URTI to LRTI (median, 16 days; range, 2-62 days). Multivariable logistic regression analyses showed that male sex, higher immunodeficiency scoring index, albumin <3 g/dL, glucose >150 mg/dL, and presence of respiratory copathogens were associated with occurrence of LRTI. Hyperglycemia with steroid use was associated with progression to LRTI (P < .01) in Cox models. LRTI with HCoV detected in BAL was associated with higher mortality than LRTI without documented detection in BAL (P < .01). In conclusion, we identified factors associated with HCoV LRTI, some of which are less commonly appreciated to be risk factors for LRTI with other respiratory viruses in HCT recipients. The association of hyperglycemia with LRTI might provide an intervention opportunity to reduce the risk of LRTI.


Asunto(s)
Infecciones por Coronavirus/epidemiología , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Infecciones del Sistema Respiratorio/epidemiología , Adolescente , Adulto , Niño , Preescolar , Infecciones por Coronavirus/etiología , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Infecciones del Sistema Respiratorio/virología , Estudios Retrospectivos , Factores de Riesgo , Estaciones del Año , Estados Unidos , Adulto Joven
8.
Rev. medica electron ; 43(1): 2942-2953,
Artículo en Español | LILACS, CUMED | ID: biblio-1156786

RESUMEN

RESUMEN La COVID 19 es una enfermedad pandémica producida por el virus SARS-CoV-2, tiene dentro de los grupos vulnerables al cáncer de pulmón por presentar una inmunodepresión adquirida por los tratamientos oncoespecíficos administrados y esto conlleva a una mayor exposición a complicaciones si se contrae esta terrible infección que azota al mundo en la actualidad. El objetivo fue exponer los riesgos y complicaciones que tienen los pacientes con cáncer de pulmón que reciben tratamientos oncoespecíficos si se infectan con el SARS-COV-2. Se realizó una revisión sistemática de los principales artículos publicados en inglés y en español por autores cubanos y extranjeros en revistas de alto impacto a nivel mundial, información reportada por la Organización Mundial de la Salud, la red de Infomed y el Ministerio de Salud Pública de Cuba. Se concluyó que los pacientes con cáncer de pulmón no presentan un riesgo superior a la población general para contraer la COVID 19, sí existe cierta evidencia de que estos pacientes puedan sufrir una infección más grave si la adquieren (AU).


SUMMARY COVID-19 is a pandemic disease produced by SARS-CoV-2 virus; the group of patients with lung cancer is vulnerable to this disease because of presenting an acquired immune depression due to administered oncospecific treatments, leading to higher exposition to complications if the patient gets this terrible disease striking worldwide nowadays. The objective of this review was exposing the risk and complications affronted by patients suffering lung cancer with oncospecific treatment if they get infected by SARS-CoV-2. The authors carried out a systematic review of the main articles published in Spanish and English by Cuban and foreign authors in high impact journals around the world, information reported by the World Health Organization, INFOMED and the Ministry of Public Health of Cuba. It was concluded that patients with lung cancer are not at a higher risk of catching COVID-19 than general population; it does exist certain evidence of that these patients could suffer a more serious infection if they get the disease (AU).


Asunto(s)
Humanos , Factores de Riesgo , Infecciones por Coronavirus/etiología , Sistema Inmunológico/fisiopatología , Neoplasias Pulmonares/complicaciones , Infecciones por Coronavirus/diagnóstico , Base de Datos , Quimioterapia , Inmunoterapia , Neoplasias Pulmonares/tratamiento farmacológico
9.
PLoS One ; 16(1): e0244476, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33406101

RESUMEN

In confronting the global spread of the coronavirus disease COVID-19 pandemic we must have coordinated medical, operational, and political responses. In all efforts, data is crucial. Fundamentally, and in the possible absence of a vaccine for 12 to 18 months, we need universal, well-documented testing for both the presence of the disease as well as confirmed recovery through serological tests for antibodies, and we need to track major socioeconomic indices. But we also need auxiliary data of all kinds, including data related to how populations are talking about the unfolding pandemic through news and stories. To in part help on the social media side, we curate a set of 2000 day-scale time series of 1- and 2-grams across 24 languages on Twitter that are most 'important' for April 2020 with respect to April 2019. We determine importance through our allotaxonometric instrument, rank-turbulence divergence. We make some basic observations about some of the time series, including a comparison to numbers of confirmed deaths due to COVID-19 over time. We broadly observe across all languages a peak for the language-specific word for 'virus' in January 2020 followed by a decline through February and then a surge through March and April. The world's collective attention dropped away while the virus spread out from China. We host the time series on Gitlab, updating them on a daily basis while relevant. Our main intent is for other researchers to use these time series to enhance whatever analyses that may be of use during the pandemic as well as for retrospective investigations.


Asunto(s)
COVID-19/psicología , Pandemias/estadística & datos numéricos , Medios de Comunicación Sociales/tendencias , Atención , COVID-19/etiología , Infecciones por Coronavirus/etiología , Infecciones por Coronavirus/psicología , Humanos , Lenguaje , Estudios Retrospectivos , SARS-CoV-2/patogenicidad
10.
Onderstepoort J Vet Res ; 87(1): e1-e9, 2020 Dec 21.
Artículo en Inglés | MEDLINE | ID: mdl-33354975

RESUMEN

The first known severe disease caused by a coronavirus (CoV) in humans emerged with the severe acute respiratory syndrome (SARS) epidemic in China, which killed 774 people during its 2002/2003 outbreak. The Middle East respiratory syndrome (MERS) was the second human fatal disease, which started in 2012 in Saudi Arabia and resulted in 858 fatalities. In December 2019, a new virus, SARS-CoV-2 (COVID-19), originating from China, began generating headlines worldwide because of the unprecedented speed of its transmission; 5.2 million people were infected and 338 480 had been reported dead from December 2019 to May 2020. These human coronaviruses are believed to have an animal origin and had reached humans through species jump. Coronaviruses are well known for their high frequency of recombination and high mutation rates, allowing them to adapt to new hosts and ecological niches. This review summarises existing information on what is currently known on the role of wild and domesticated animals and discussions on whether they are the natural reservoir/amplifiers hosts or incidental hosts of CoVs. Results of experimental infection and transmission using different wild, domesticated and pet animals are also reviewed. The need for a One Health approach in implementing measures and practices is highlighted to improve human health and reduce the emergence of pandemics from these zoonotic viruses.


Asunto(s)
COVID-19/epidemiología , Infecciones por Coronavirus/epidemiología , Coronavirus del Síndrome Respiratorio de Oriente Medio , SARS-CoV-2 , Zoonosis , Animales , COVID-19/etiología , COVID-19/transmisión , Camelus/virología , Quirópteros/virología , Infecciones por Coronavirus/etiología , Infecciones por Coronavirus/transmisión , Vectores de Enfermedades , Salud Global , Humanos , Salud Única , Pandemias
11.
J Prim Care Community Health ; 11: 2150132720969483, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33213266

RESUMEN

BACKGROUND: Healthcare workers (HCWs) are faced with an elevated risk of exposure to SARS-COV-2 due to the clinical procedures they perform on COVID-19 patients. However, data for frontline HCWs level of exposure and risk of COVID-19 virus infection are limited. OBJECTIVE: We investigated the level of exposure and risk of COVID-19 virus infection among HCWs in COVID-19 treatment centers in Ghana. METHODS: A cross-sectional study was utilized in this study and HCWs were invited by convenience to participate in the study, 408 HCWs in 4 COVID-19 treatment centers participated in the study. Adherence to infection prevention and control (IPC) measures were used to categorized HCWs as low or high risk of COVID-19 virus infection. The WHO COVID-19 risk assessment tool was used to collect quantitative data from the study participants. RESULTS: There was a high (N = 328, 80.4%) level of occupational exposure to the COVID-19 virus. However, only 14.0% of the exposed HCWs were at high risk of COVID-19 virus infection. Healthcare workers who performed or were present during any aerosol-generating procedures (AGP) were 23.8 times more likely to be exposed compared to HCWs who did not perform or were absent during any AGP (AOR 23.83; 95% CI: 18.45, 39.20). High risk of COVID-19 virus infection was less likely among registered nurses (AOR = 0.09; 95% CI: 0.02, 0.60), HCWs who performed or were present during any AGP (AOR = 0.05; 95% CI: 0.01, 0.50) and HCWs with a master's degree qualification (AOR 0.06; 95% CI: 0.01, 0.63). CONCLUSION: Despite the high level of exposure to the COVID-19 virus among HCWs in the treatment centers, only 14.0% were at high risk of COVID-19 virus infection. To protect this group of HCWs, treatment centers and HCWs should continue to adhere to WHO and national IPC protocols in managing of COVID-19 cases.


Asunto(s)
Infecciones por Coronavirus/etiología , Personal de Salud/estadística & datos numéricos , Neumonía Viral/etiología , Medición de Riesgo , Adulto , COVID-19 , Infecciones por Coronavirus/prevención & control , Infecciones por Coronavirus/transmisión , Estudios Transversales , Femenino , Ghana/epidemiología , Humanos , Transmisión de Enfermedad Infecciosa de Paciente a Profesional/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Enfermeras y Enfermeros/estadística & datos numéricos , Exposición Profesional/prevención & control , Exposición Profesional/estadística & datos numéricos , Pandemias/prevención & control , Neumonía Viral/prevención & control , Neumonía Viral/transmisión , Embarazo , Medición de Riesgo/métodos , Factores de Riesgo , Encuestas y Cuestionarios , Adulto Joven
12.
Clin Cardiol ; 43(12): 1362-1367, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-33176009

RESUMEN

COronavirus Infectious Disease which started in 2019 (COVID-19) usually presents with the signs and symptoms of pneumonia. However, a growing number of recent reports highlight the fact that the infection may be by far more than only a respiratory disease. There is evidence of an increased thromboembolic risk in COVID-19 patients, with a variety of manifestations in terms of ischemic stroke, deep vein thrombosis, acute pulmonary embolism, acute myocardial infarction, systemic arterial embolism, and placental thrombosis. The German physician Rudolph Virchow, about two centuries ago, described three pivotal factors contributing together to thromboembolic risk: endothelial injury, hypercoagulability, and blood stasis. COVID-19-associated hypercoagulability is unique and distinctive, and has its own features involving the immune system. Many of the drugs proposed and currently undergoing evaluation for the treatment of COVID-19 have one or more of the Virchow's triad elements as a target. The three factors outlined by Virchow are still able to explain the venous and arterial hypercoagulable state in the dramatic COVID-19 setting. Nowadays, we have decidedly more sophisticated diagnostic tools than Virchow had, but many of the challenges that we are facing are the same as Virchow faced in the 19th century.


Asunto(s)
COVID-19/complicaciones , Infecciones por Coronavirus/etiología , Tromboembolia/etiología , COVID-19/fisiopatología , Infecciones por Coronavirus/fisiopatología , Ventrículos Cardíacos/fisiopatología , Hemodinámica , Humanos , Tromboembolia/fisiopatología
13.
Circ Cardiovasc Interv ; 13(11): e010027, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-33167699

RESUMEN

BACKGROUND: The optimal treatment strategy for treating ST-segment-elevation myocardial infarction (STEMI) in context of the coronavirus disease 2019 (COVID-19) pandemic is unclear given the potential risk of occupational exposure during primary percutaneous coronary intervention (PPCI). We quantified the impact of different STEMI treatment strategies on patient outcomes and provider risk in context of the COVID-19 pandemic. METHODS: Using a decision-analytic framework, we evaluated the effect of PPCI versus the pharmaco-invasive strategy for managing STEMI on 30-day patient mortality and individual provider infection risk based on presence of cardiogenic shock, suspected coronary territory, and presence of known or presumptive COVID-19 infection. RESULTS: For patients with low suspicion for COVID-19, PPCI had mortality benefit over the pharmaco-invasive strategy, and the risk of cardiac catheterization laboratory provider infection remained very low (<0.25%) across all subgroups. For patients with presumptive COVID-19 with cardiogenic shock, PPCI offered substantial mortality benefit to patients relative to the pharmaco-invasive strategy (7.9% absolute decrease in 30-day mortality), but also greater risk of provider infection (2.3% absolute increase in risk of provider infection). For patients with presumptive COVID-19 with nonanterior STEMI without cardiogenic shock, PPCI offered a 0.4% absolute mortality benefit over the pharmaco-invasive strategy with a 0.2% greater absolute risk of provider infection, and the tradeoff between patient and provider risk with PPCI became more apparent in sensitivity analysis with more severe COVID-19 infections. CONCLUSIONS: Usual care with PPCI remains the appropriate treatment strategy in the majority of cases presenting with STEMI in the setting of the COVID-19 pandemic. However, utilization of a pharmaco-invasive strategy in selected patients with STEMI with presumptive COVID-19 and low likelihood of mortality from STEMI and use of preventive strategies such as preprocedural intubation in high risk patients when PPCI is the preferred strategy may be reasonable to reduce provider risk of COVID-19 infection.


Asunto(s)
Betacoronavirus , Infecciones por Coronavirus/etiología , Personal de Salud , Exposición Profesional/efectos adversos , Intervención Coronaria Percutánea/efectos adversos , Neumonía Viral/etiología , Infarto del Miocardio con Elevación del ST/terapia , Anciano , COVID-19 , Infecciones por Coronavirus/prevención & control , Técnicas de Apoyo para la Decisión , Humanos , Persona de Mediana Edad , Pandemias/prevención & control , Neumonía Viral/prevención & control , Riesgo , SARS-CoV-2 , Infarto del Miocardio con Elevación del ST/mortalidad
14.
JAMA Netw Open ; 3(10): e2026373, 2020 10 01.
Artículo en Inglés | MEDLINE | ID: mdl-33119111

RESUMEN

Importance: Policy makers have relaxed restrictions for certain nonessential industries, including construction, jeopardizing the effectiveness of social distancing measures and putting already at-risk populations at greater risk of coronavirus disease 2019 (COVID-19) infection. In Texas, Latinx populations are overly represented among construction workers, and thus have elevated rates of exposure that are compounded by prevalent high-risk comorbidities and lack of access to health care. Objective: To assess the association between construction work during the COVID-19 pandemic and hospitalization rates for construction workers and the surrounding community. Design, Setting, and Participants: This decision analytical model used a mathematical model of COVID-19 transmission, stratified by age and risk group, with construction workers modeled explicitly. The model was based on residents of the Austin-Round Rock metropolitan statistical area, with a population of 2.17 million. Based on 500 stochastic simulations for each of 15 scenarios that varied the size of the construction workforce and level of worksite transmission risk, the association between continued construction work and hospitalizations was estimated and then compared with anonymized line-list hospitalization data from central Texas through August 20, 2020. Exposures: Social distancing interventions, size of construction workforce, and level of disease transmission at construction worksites. Main Outcomes and Measures: For each scenario, the total number of COVID-19 hospitalizations and the relative risk of hospitalization among construction workers was projected and then compared with relative risks estimated from reported hospitalization data. Results: Allowing unrestricted construction work was associated with an increase of COVID-19 hospitalization rates through mid-August 2020 from 0.38 per 1000 residents to 1.5 per 1000 residents and from 0.22 per 1000 construction workers to 9.3 per 1000 construction workers. This increased risk was estimated to be offset by safety measures (such as thorough cleaning of equipment between uses, wearing of protective equipment, limits on the number of workers at a worksite, and increased health surveillance) that were associated with a 50% decrease in transmission. The observed relative risk of hospitalization among construction workers compared with other occupational categories among adults aged 18 to 64 years was 4.9 (95% CI, 3.8-6.2). Conclusions and Relevance: The findings of this study suggest that unrestricted work in high-contact industries, such as construction, is associated with a higher level of community transmission, increased risks to at-risk workers, and larger health disparities among members of racial and ethnic minority groups.


Asunto(s)
Industria de la Construcción , Infecciones por Coronavirus/etiología , Hospitalización , Exposición Profesional/efectos adversos , Pandemias , Neumonía Viral/etiología , Adolescente , Adulto , Betacoronavirus , COVID-19 , Comorbilidad , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/etnología , Infecciones por Coronavirus/virología , Etnicidad , Femenino , Hispánicos o Latinos , Humanos , Masculino , Persona de Mediana Edad , Grupos Minoritarios , Neumonía Viral/epidemiología , Neumonía Viral/etnología , Neumonía Viral/virología , Grupos Raciales , Características de la Residencia , Factores de Riesgo , SARS-CoV-2 , Seguridad , Texas/epidemiología , Lugar de Trabajo , Adulto Joven
15.
World J Gastroenterol ; 26(37): 5534-5542, 2020 Oct 07.
Artículo en Inglés | MEDLINE | ID: mdl-33088153

RESUMEN

The first cases of a novel corona virus infection were reported in Wuhan China in December of 2019, followed by the declaration of an international pandemic by the World Health Organization in March 2020. Early reports of the virus, now known as severe acute respiratory syndrome coronavirus 2, and its clinical disease coronavirus disease 2019 (COVID-19), has shown higher rates of morbidity and mortality in the elderly and those with pre-existing medical conditions. Of particular concern is the safety of those with compromised immune systems. Inflammatory Bowel disease (IBD) is itself caused by a disordered immune response, with the most effective medical therapies being immune suppressing or modifying. As such, the risk of COVID-19, virus related outcomes, and appropriate management of IBD patients during the global pandemic is of immediate concern to gastroenterologists worldwide. There has been a rapid accumulation of clinical data and expert opinion on the topic. This review will highlight the latest source information on clinical observation/outcomes of the IBD population and provide a concise summary of the most up to date perspectives on IBD management in the age of COVID-19.


Asunto(s)
Betacoronavirus , Infecciones por Coronavirus/prevención & control , Enfermedades Inflamatorias del Intestino/complicaciones , Enfermedades Inflamatorias del Intestino/terapia , Pandemias/prevención & control , Neumonía Viral/prevención & control , COVID-19 , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/etiología , Infecciones por Coronavirus/terapia , Salud Global , Humanos , Enfermedades Inflamatorias del Intestino/inmunología , Neumonía Viral/diagnóstico , Neumonía Viral/etiología , Neumonía Viral/terapia , Medición de Riesgo , Factores de Riesgo , SARS-CoV-2
16.
Adv Genet ; 106: 119-122, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33081921

RESUMEN

WHO's pronouncement of the 2019 novel coronavirus outbreak as a pandemic disease came months after we published a warning that the present deepest minimum of the sunspot cycle would be likely to facilitate the onset of a viral pandemic. During a deep sunspot minimum (deepest in 100 years) such as we are now witnessing, two space related phenomena could have an effect on the disposition of viral disease and potential pandemics. With the weakening of the magnetic field in the Earth's vicinity, there would be a high flux of mutagenic cosmic rays. These processes would be likely to herald the onset of new pandemics. Neutron counts from Moscow Neutron Monitor show that the flux of cosmic rays reaching Earth in 2019 was indeed at a maximum over a timespan of half a century since 1962. It is of interest to note that immediately prior to the first recorded cases of the novel Corona virus in China a peak of cosmic rays was measured as is indicated by the Huon neutron monitor data. Recent research revealed that estimates of the timing of the most recent common ancestor of COVID-19 made with current sequence data point to emergence of the virus in late November 2019 to early December 2019, compatible with the earliest retrospectively confirmed cases and the cosmic ray spike in late November 2019. In our view, this strong cosmic ray spike was in some way connected with the onset of the outbreak.


Asunto(s)
Evolución Biológica , Infecciones por Coronavirus/etiología , Radiación Cósmica , Neumonía Viral/etiología , Actividad Solar , Betacoronavirus/fisiología , Betacoronavirus/efectos de la radiación , COVID-19 , Enfermedades Transmisibles Emergentes/epidemiología , Enfermedades Transmisibles Emergentes/etiología , Enfermedades Transmisibles Emergentes/virología , Infecciones por Coronavirus/epidemiología , Radiación Cósmica/efectos adversos , Planeta Tierra , Historia del Siglo XXI , Humanos , Neutrones , Pandemias , Neumonía Viral/epidemiología , SARS-CoV-2
17.
Adv Genet ; 106: 75-100, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33081928

RESUMEN

The origins and global spread of two recent, yet quite different, pandemic diseases is discussed and reviewed in depth: Candida auris, a eukaryotic fungal disease, and COVID-19 (SARS-CoV-2), a positive strand RNA viral respiratory disease. Both these diseases display highly distinctive patterns of sudden emergence and global spread, which are not easy to understand by conventional epidemiological analysis based on simple infection-driven human- to-human spread of an infectious disease (assumed to jump suddenly and thus genetically, from an animal reservoir). Both these enigmatic diseases make sense however under a Panspermia in-fall model and the evidence consistent with such a model is critically reviewed.


Asunto(s)
Evolución Biológica , Candidiasis/etiología , Enfermedades Transmisibles Emergentes/etiología , Infecciones por Coronavirus/etiología , Origen de la Vida , Neumonía Viral/etiología , Animales , Betacoronavirus/aislamiento & purificación , Betacoronavirus/fisiología , COVID-19 , Candida/aislamiento & purificación , Candida/fisiología , Candidiasis/epidemiología , Enfermedades Transmisibles Emergentes/epidemiología , Coronavirus/aislamiento & purificación , Coronavirus/fisiología , Infecciones por Coronavirus/epidemiología , Planeta Tierra , Exobiología , Medio Ambiente Extraterrestre , Interacciones Huésped-Patógeno/fisiología , Humanos , Pandemias , Neumonía Viral/epidemiología , SARS-CoV-2
18.
Eur J Cardiothorac Surg ; 58(5): 899-906, 2020 11 01.
Artículo en Inglés | MEDLINE | ID: mdl-33084868

RESUMEN

OBJECTIVES: Few anecdotal cases have been reported in the literature regarding heart transplant recipients and infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report our experience with 6 patients hospitalized in Northern Italy during the outbreak. METHODS: Of the 396 living heart transplant recipients from 1985 to 2020 included in the study, 6 patients developed the novel 2019 coronavirus disease. Risk factors, last follow-up characteristics, onset presentation, in-hospital course of disease and blood examinations data were collected for these patients. RESULTS: All patients were symptomatic and had positive results from a nasopharyngeal swab test for SARS-CoV-2. Of the 6 patients, 5 were hospitalized and 1 remained self-quarantined at home. Two patients died and 3 were discharged home. Two patients were admittted to the intensive care unit . Immunosuppressive therapy was modified with a median reduction comprising doses that were 50% cyclosporine and 50% mycophenolate. All patients received a medium-dose of corticosteroids as a bolus medication in addition to their therapy. All hospitalized patients received hydroxychloroquine; 2 patients received ritonavir/lopinavir. Broad-spectrum antibiotics for prophylaxis were administered to all. One patient had an ischaemic stroke and died of sepsis. CONCLUSIONS: In the absence of any strong evidence regarding the treatment of heart transplant recipients infected with SARS-CoV-2, we faced a new challenge in managing viral infection in an immunosuppressed population. Because immunomodulation interaction with the infection seems to be crucial for developing severe forms of the disease, we managed to reduce immunosuppressive therapy by adding medium doses of corticosteroids. Despite the limited number of affected patients, this report suggests that special considerations should be given to treating coronavirus disease in the heart transplant recipient population.


Asunto(s)
Betacoronavirus , Infecciones por Coronavirus/etiología , Trasplante de Corazón , Neumonía Viral/etiología , Complicaciones Posoperatorias/etiología , Anciano , Anciano de 80 o más Años , Betacoronavirus/aislamiento & purificación , COVID-19 , Prueba de COVID-19 , Técnicas de Laboratorio Clínico , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/terapia , Femenino , Estudios de Seguimiento , Humanos , Italia , Masculino , Persona de Mediana Edad , Pandemias , Neumonía Viral/diagnóstico , Neumonía Viral/epidemiología , Neumonía Viral/terapia , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/terapia , Factores de Riesgo , SARS-CoV-2
19.
Eur J Cardiothorac Surg ; 58(5): 991-996, 2020 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-33084869

RESUMEN

OBJECTIVES: We reviewed the incidence of coronavirus disease 2019 cases and the postoperative outcomes of patients who had thoracic surgery during the beginning and at the highest point of transmission in our community. METHODS: We retrospectively reviewed patients who had undergone elective thoracic surgery from 12 February 2020 to 30 April 2020 and were symptomatic or tested positive for severe acute respiratory syndrome coronavirus 2 infection within 14 days after surgery, with a focus on their complications and potential deaths. RESULTS: Out of 101 surgical procedures, including 57 primary oncological resections, 6 lung transplants and 18 emergency procedures, only 5 cases of coronavirus disease 2019 were identified, 3 in the immediate postoperative period and 2 as outpatients. All 5 patients had cancer; the median age was 64 years. The main virus-related symptom was fever (80%), and the median onset of coronavirus disease 2019 was 3 days. Although 80% of the patients who had positive test results for severe acute respiratory syndrome coronavirus 2 required in-hospital care, none of them were considered severe or critical and none died. CONCLUSIONS: These results indicate that, in properly selected cases, with short preoperative in-hospital stays, strict isolation and infection control protocols, managed by a dedicated multidisciplinary team, a surgical procedure could be performed with a relatively low risk for the patient.


Asunto(s)
Betacoronavirus , Carcinoma de Células Escamosas/cirugía , Infecciones por Coronavirus/etiología , Procedimientos Quirúrgicos Electivos , Neoplasias Pulmonares/cirugía , Neumonía Viral/etiología , Complicaciones Posoperatorias , Procedimientos Quirúrgicos Torácicos , Adulto , Anciano , Betacoronavirus/aislamiento & purificación , COVID-19 , Prueba de COVID-19 , Técnicas de Laboratorio Clínico , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/terapia , Femenino , Estudios de Seguimiento , Humanos , Incidencia , Masculino , Evaluación de Resultado en la Atención de Salud , Pandemias , Neumonía Viral/diagnóstico , Neumonía Viral/epidemiología , Neumonía Viral/terapia , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/terapia , Estudios Retrospectivos , SARS-CoV-2 , España , Resultado del Tratamiento
20.
Medicine (Baltimore) ; 99(42): e22688, 2020 Oct 16.
Artículo en Inglés | MEDLINE | ID: mdl-33080715

RESUMEN

BACKGROUND: Unknown origin pneumonia has been furiously spreading since the late of December 2019, subsequently spread to approximately all provinces and areas in China and many countries, which was announced as a Public Health Emergency of International Concern by World Health Organization (WHO). The studies on 2019 Corona Virus Disease-19 (COVID-19) conducted from various fields around the world. Herein, the objective of the present study is to summarize the etiology, epidemiology, clinical manifestations, image findings, traceability analysis, and drug development of COVID-19. METHODS: The following electronic databases were searched: Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database, VIP Chinese Science and Technology Periodical Database, and Wanfang Data. Other relevant literature will be manually searched as a compliment. We have reviewed etiology, epidemiology, clinical manifestations, image findings, and medication from case reports and retrospective clinical studies relating to COVID-19 published since the outbreak. RESULTS: The coronavirus is closely related to bat coronavirus and pangolin coronavirus. Besides, the infection pathway is confirmed to be the respiratory and digestive systems. The virus indicates person-to-person transmission and some patients present asymptomatic. The elderly have a higher mortality rate. Rapid and sensitive nucleic acid testing is usually used as a basis for diagnosis. Currently, there is no specific vaccine and antiviral drug. Intervention actions such as travel bans and quarantine adopted have effectively reduced the spread of the epidemic. CONCLUSION: This systemic review will provide high-quality evidence to summarize etiology, epidemiology, clinical manifestations, image findings, traceability analysis, drug development in patients with COVID-19.


Asunto(s)
Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/fisiopatología , Neumonía Viral/epidemiología , Neumonía Viral/fisiopatología , Corticoesteroides/uso terapéutico , Factores de Edad , Enzima Convertidora de Angiotensina 2 , Antivirales/uso terapéutico , Betacoronavirus , COVID-19 , China , Comorbilidad , Infecciones por Coronavirus/etiología , Infecciones por Coronavirus/terapia , Citocinas/metabolismo , Humanos , Inmunoglobulinas/uso terapéutico , Pulmón/diagnóstico por imagen , Pulmón/patología , Pandemias , Peptidil-Dipeptidasa A/metabolismo , Neumonía Viral/etiología , Neumonía Viral/terapia , Pronóstico , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , SARS-CoV-2 , Factores Sexuales
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...